Liquid‑biopsy firm Syantra launched a multicenter, 2,000‑subject study to support clinical implementation and market access for Onco‑ID Breast, its whole‑blood mRNA assay for early breast cancer detection in high‑risk women. The study, led by Weill Cornell Medicine with partners including the University of Calgary and Vincere Cancer Center, focuses on women with dense breasts where mammography sensitivity is limited. Syantra’s test measures immune‑related epigenetic shifts in whole blood rather than tumor cfDNA, aiming to detect early disease by the host response. The company aims to use the trial to validate clinical performance and reduce imaging false positives, a major limitation in dense-breast screening. If the study validates the assay’s sensitivity and specificity in this population, Syantra expects to support clinical adoption and payer discussions for a risk‑stratified screening pathway that complements existing imaging modalities.